Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1730796 | 0.97 | F2R (0.46) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL1729318 | 0.92 | F2R (0.45) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL1730570 | 0.91 | F2R (0.46) | F2RKDM4EMAPTRAB9ANPC1 | |
| Trifluoroacetic Acid SCHEMBL1729292 | 0.88 | F2R (0.42) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL1730830 | 0.88 | F2R (0.43) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL1729261 | 0.88 | F2R (0.49) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL1729351 | 0.88 | F2R (0.47) | F2RKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL1732305 | 0.87 | F2R (0.44) | F2R | |
| SCHEMBL1729310 | 0.87 | F2R (0.60) | F2RMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1730225 | 0.87 | F2R (0.44) | F2RKDM4EMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | claimed |
| EP-2385039-B1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | EISAI R&D MAN CO LTD (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-1614680-B1 | Process for preparing 2-iminopyrrolidine derivatives | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-2385039-A1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | Eisai R&D Management Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2290/4885KDM4E 3161/4885MAPT 3483/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | F2R 2289/4885KDM4E 3132/4885MAPT 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.